Robert Ross Carter's most recent trade in Oncology Institute Inc (The) was a trade of 1,601 Class A Common Stock done at an average price of $2.7 . Disclosure was reported to the exchange on May 21, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Oncology Institute Inc (The) | Robert Ross Carter | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 2.68 per share. | 21 May 2025 | 1,601 | 235,174 | - | 2.7 | 4,283 | Class A Common Stock |
| Oncology Institute Inc (The) | Robert Ross Carter | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 197,368 | 236,775 | - | 0 | Class A Common Stock | |
| Oncology Institute Inc (The) | Robert Ross Carter | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.04 per share. | 26 Mar 2025 | 9,056 | 39,407 | - | 1.0 | 9,434 | Common Stock |
| Oncology Institute Inc (The) | Robert Ross Carter | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 26 Mar 2025 | 4,528 | 4,528 | - | - | Common Warrant | |
| Oncology Institute Inc (The) | Robert Ross Carter | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.89 per share. | 19 Mar 2025 | 1,150 | 30,351 | - | 0.9 | 1,022 | Class A Common Stock |
| Oncology Institute Inc (The) | Robert Ross Carter | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.14 per share. | 20 Nov 2024 | 235 | 31,759 | - | 0.1 | 32 | Class A Common Stock |